65,437 trials
Osteoporosis
Primary: Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26 — 8.6; 31.0 Percentage of Participants — p=<0.001
Coronary Disease · Coronary Artery Disease · Coronary Artery Stenosis
Primary: In-stent Late Loss (LL) — 0.052; 0.238 millimeters
Parkinson's Disease
Primary: Fall Frequency Per Day — 0.13; 0.25 Number Falls/Day — p=0.049
Staphylococcus Aureus Infection
Primary: Geometric Mean Fold-rise (GMFR) in 0657n-specific Immunoglobulin G (IgG) Antibody Concentration From Baseline to 28 Days After the Administration of the Second V710…
Unspecified Threat to Breathing
Primary: Respiration Rate Accuracy - Mean Difference in Breaths Per Minute Between the BM07 5GHz Sensor and SomnoScreen Devices — 0.28 breaths per minute
Hepatitis B · Chronic Hepatitis B
Primary: Change in Mean Hepatitis B Virus (HBV) DNA Levels — 10.290; 9.721; 3.669; 3.194 log10 copies/mL
Scalp Seborrheic Dermatitis
Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants
Healthy or Stable Underlying Chronic Medical Condition
Primary: The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the…
Pain
Primary: Average Pain Score at Rest — 3.1; 2.9 Units on a scale
Disease
Primary: Number of Participants Using Evidence-based Template to Document Asthma Care Within an Electronic Medical Record — 41; 11 participants — p=.01
Alcohol Abuse
Primary: Amount of Alcohol Consumed — 3.46; 2.36 Number of drinks consumed
Safety and Tolerability of EGT0001474 in Healthy Volunteers
Primary: Cmax — 12.7; 28; 90.7; 194 ng/ml
Hypercholesterolemia
Primary: Changes in Small Dense Low-density Lipoprotein Cholesterol (sdLDL-C) Levels — -42; -46 sdLDL-C, mg/dL
Xerophthalmia · Blepharitis
Primary: Visual Analog Score (VAS) — 21.55; 27.27 scores on a scale — p=>0.05